Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Analysis of Profitability Ratios
- Net Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Current Ratio since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Return on Invested Capital (ROIC)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Invested capital2 | ||||||
Performance Ratio | ||||||
ROIC3 | ||||||
Benchmarks | ||||||
ROIC, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2024 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The financial data reveals notable trends concerning net operating profit after taxes (NOPAT), invested capital, and return on invested capital (ROIC) over the five-year period ending December 31, 2024.
- Net Operating Profit After Taxes (NOPAT)
- There was an initial increase in NOPAT from 6,545 million USD in 2020 to a peak of 7,465 million USD in 2021, representing improved operating profitability. However, this was followed by a decline over the next two years, with NOPAT decreasing to 6,425 million USD in 2022 and further dropping to 5,117 million USD in 2023. A slight recovery is seen in 2024 with NOPAT rising to 5,400 million USD, although it remains below the levels of 2020 and 2021.
- Invested Capital
- Invested capital has shown a consistently upward trajectory from 61,158 million USD in 2020 to 85,573 million USD by the end of 2023, indicating increased capital deployment. A moderate decrease to 82,071 million USD is observed in 2024, suggesting a possible capital reallocation or divestment phase.
- Return on Invested Capital (ROIC)
- ROIC exhibits a declining trend over the entire period, starting from 10.7% in 2020 and decreasing steadily each year to 5.98% in 2023. A minor improvement to 6.58% is noted in 2024 but remains substantially lower than the starting point. This overall decline signals a reduction in the efficiency with which capital is generating returns.
In summary, the data indicates that while capital investment increased significantly until 2023, operating profitability experienced volatility with a peak in 2021 followed by declines and only modest recovery in 2024. The return on invested capital declined correspondingly, pointing to a decreasing effectiveness in generating earnings from the invested capital base during this timeframe.
Decomposition of ROIC
ROIC | = | OPM1 | × | TO2 | × | 1 – CTR3 | |
---|---|---|---|---|---|---|---|
Dec 31, 2024 | = | × | × | ||||
Dec 31, 2023 | = | × | × | ||||
Dec 31, 2022 | = | × | × | ||||
Dec 31, 2021 | = | × | × | ||||
Dec 31, 2020 | = | × | × |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
- Operating Profit Margin (OPM)
- The operating profit margin shows a declining trend from 24.12% in 2020 to 15.91% in 2023, indicating a reduction in profitability relative to sales over this period. However, there is a slight recovery projected in 2024, with the margin increasing to 17.13%, suggesting an improvement in operational efficiency or cost management during that year.
- Turnover of Capital (TO)
- The turnover of capital remains relatively stable between 0.49 and 0.54 throughout the years, with minor fluctuations. It decreased slightly from 0.53 in 2020 to 0.49 in 2021, then increased back to 0.54 in 2022, followed by a small decline to 0.50 in 2023, and a slight increase again to 0.52 in 2024. This stability indicates consistent effectiveness in utilizing capital to generate revenue.
- Effective Cash Tax Rate (1 - CTR)
- This metric exhibits a gradual decline from 84.21% in 2020 to 73.51% in 2024. This decreasing trend suggests a rising effective cash tax rate over time, implying that the company is retaining less of its earnings after tax, which might have an impact on net profitability and cash flow availability.
- Return on Invested Capital (ROIC)
- The return on invested capital demonstrates a clear downward trend from 10.7% in 2020 to a low of 5.98% in 2023, reflecting a reduction in the efficiency and profitability of the company's capital investments. A slight improvement is anticipated in 2024, increasing to 6.58%. Although this indicates some recovery, the overall decline may point to challenges in generating returns on invested funds over the observed period.
Operating Profit Margin (OPM)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Add: Cash operating taxes2 | ||||||
Net operating profit before taxes (NOPBT) | ||||||
Revenues | ||||||
Profitability Ratio | ||||||
OPM3 | ||||||
Benchmarks | ||||||
OPM, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2024 Calculation
OPM = 100 × NOPBT ÷ Revenues
= 100 × ÷ =
4 Click competitor name to see calculations.
The financial data reveals several notable trends over the five-year period from 2020 to 2024.
- Net Operating Profit Before Taxes (NOPBT)
- The net operating profit before taxes exhibited a fluctuating pattern. It increased significantly from 7,773 million US dollars in 2020 to a peak of 9,330 million US dollars in 2021. Subsequently, it declined to 8,231 million in 2022 and further dropped to its lowest point of 6,818 million in 2023. In 2024, a partial recovery occurred, with NOPBT rising again to 7,346 million US dollars, although it remained below earlier peak levels.
- Revenues
- Revenues demonstrated an overall upward trend during the period. Beginning at 32,218 million US dollars in 2020, revenues increased steadily to reach 44,915 million in 2022. However, a slight decrease was observed in 2023, with revenues falling to 42,857 million US dollars, after which the revenue level stabilized somewhat, ending at 42,879 million in 2024.
- Operating Profit Margin (OPM)
- The operating profit margin declined consistently over the period. Starting at 24.12% in 2020, the margin slightly decreased to 23.79% in 2021 before experiencing a sharper decline to 18.33% in 2022. The downward trend continued into 2023, reaching 15.91%, and only slightly improved to 17.13% in 2024. This trend indicates a reduction in profitability relative to revenues over the years.
In summary, while revenues grew substantially from 2020 through 2022 before plateauing, net operating profit showed volatility and a declining trend after 2021, with only partial recovery in the last reported year. The consistent decline in operating profit margin suggests a decrease in operational efficiency or increased cost pressures impacting profitability despite higher revenue figures in the earlier years.
Turnover of Capital (TO)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Revenues | ||||||
Invested capital1 | ||||||
Efficiency Ratio | ||||||
TO2 | ||||||
Benchmarks | ||||||
TO, Competitors3 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Invested capital. See details »
2 2024 Calculation
TO = Revenues ÷ Invested capital
= ÷ =
3 Click competitor name to see calculations.
- Revenue Trend
- Over the five-year period, revenues exhibited overall growth, rising from $32,218 million in 2020 to a peak of $44,915 million in 2022. However, revenues declined slightly in the subsequent years, reaching $42,857 million in 2023 and remaining relatively flat at $42,879 million in 2024. This indicates a slowing in revenue growth following the strong increases in the first three years.
- Invested Capital Trend
- Invested capital demonstrated an upward trend from 2020 through 2023, increasing from $61,158 million to $85,573 million. In 2024, invested capital decreased to $82,071 million after peaking the previous year. This pattern suggests ongoing investment in assets or operations until 2023, followed by a slight reduction or divestment in 2024.
- Turnover of Capital (TO) Ratio
- The turnover of capital ratio fluctuated moderately during the period. It started at 0.53 in 2020, declined to 0.49 in 2021, increased again to 0.54 in 2022, dropped to 0.50 in 2023, and rose to 0.52 in 2024. These variations indicate some inconsistency in how effectively the invested capital was utilized to generate revenues, with no clear sustained trend upwards or downwards.
- Overall Insights
- The data suggest that although revenue experienced significant growth earlier in the period, it plateaued and slightly decreased in later years. Concurrent investment increases in capital until 2023 likely supported earlier revenue growth, but the subsequent decline in invested capital may reflect adjustments to asset management or strategic shifts. The turnover ratio’s oscillations reflect varying efficiency in using invested capital to generate revenues, without substantial improvement or deterioration over the period analyzed.
Effective Cash Tax Rate (CTR)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Add: Cash operating taxes2 | ||||||
Net operating profit before taxes (NOPBT) | ||||||
Tax Rate | ||||||
CTR3 | ||||||
Benchmarks | ||||||
CTR, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2024 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =
4 Click competitor name to see calculations.
The financial data reveals notable trends in cash operating taxes, net operating profit before taxes (NOPBT), and the effective cash tax rate over the five-year period ending December 31, 2024.
- Cash Operating Taxes
- There is an overall increasing trend in cash operating taxes paid, rising from $1,227 million in 2020 to $1,946 million in 2024. After a significant increase from 2020 to 2021, cash operating taxes experience a slight decline in 2022 and 2023, followed by a rebound in 2024.
- Net Operating Profit Before Taxes (NOPBT)
- NOPBT exhibits variability over the period. It increased significantly from $7,773 million in 2020 to a peak of $9,330 million in 2021. Thereafter, it declined steadily, reaching a low of $6,818 million in 2023 before slightly recovering to $7,346 million in 2024. This indicates some operational challenges or market factors negatively impacting profitability post-2021.
- Effective Cash Tax Rate (CTR)
- The effective cash tax rate shows a clear upward trajectory, increasing each year from 15.79% in 2020 to 26.49% in 2024. This steady rise suggests either changes in tax regulations, reduced tax credits, or shifts in the company's geographic or operational tax structure contributing to a higher tax burden over time.
In summary, while net operating profit before taxes peaked in 2021 and subsequently declined, cash operating taxes have generally increased, driven in part by a growing effective cash tax rate. These combined trends suggest a tightening margin in terms of after-tax profitability, warranting continued attention to tax planning and operational efficiency to sustain financial performance.